Last checked at 29 Aug 2014 05:24
- Home
- Share Prices
- AQSE Share Prices
- Euronext
- Stock Screeners
- Share Chat
- FX
- News & RNS
- Events
- Media
- Trading Brokers
- Finance Tools
- Members
Latest Share Chat
Reneuron Share News (RENE)
RENE Share
Price
RENE Share
News
RENE Share
Chat
RENE Share
Trades
RENE
Live RNS
RENE Share
Charts
RENE Level 2
Console
RENE Live
Share Price
RENE Broker
Ratings
RENE Directors
Deals
RENE Financial
Diary
RENE
Fundamentals
RENE Short
Positions
RENE
Media
Reneuron Information
- This share is currently suspended. It was suspended at a price of 3.275
Share Price Information for Reneuron (RENE)
Share Price is delayed by 15 minutes
Get Live Data
Share Price:
3.275
Bid:
0.00
Ask:
0.00
Change:
0.00 (0.00%)
Spread:
0.00 (0.00%)
Open:
0.00
High:
0.00
Low:
0.00
Prev. Close:
3.275
Last checked at -
Watchlists are a member only feature
Login to your account
Don't have an account? Click here to register.ReNeuron storms on 'exciting' eye disease trial success
Wed, 20th Feb 2019 08:21
(Sharecast News) - ReNeuron Group bounded upward on Wednesday after reporting that its cell-based therapy is showing signs that it can improve the sight of patients suffering from retinitis pigmentosa, which causes blindness.The cell-based therapeutics specialist currently carrying out a US-based phase I/II clinical on people with the disease, and reported that the first three patients in a group taking part in the phase II portion of the study were able on average able to read an additional three lines of on the standard ETDRS eye chart after receiving treatment.The trial's principal investigator, Jason Comander, associate director of Inherited Retinal Disorders Service at Massachusetts Eye and Ear, and assistant professor at Harvard Medical School, said: "It is exciting to move into a population of patients whose remaining vision and retinal architecture support the possibility of visual improvement and I am very much looking forward to obtaining additional results from this patient cohort and the next."The treatment being trialled involves the use human retinal progenitor cells developed by ReNeuron, which were shown to have the potential to preserve existing photoreceptors found in the retina during pre-clinical trials.The AIM traded company said that these progenitor cells have been shown to mature into functional photoreceptors that could then help restore sight.Olav Hellebø, chief executive of ReNeuron, said: "We are excited by both the speed and extent of improvement observed in this first patient cohort in the Phase II part of the ongoing Phase I/II study with our hRPC cell therapy candidate in retinitis pigmentosa. We will continue to generate further data to assess durability of effect and efficacy in a larger number of patients in the months ahead."ReNeuron Group's shares were up 14.74% at 54.50p at 1102 GMT.
More News
28 Aug 2014 15:11
28 Aug 2014 05:31
27 Aug 2014 15:25
27 Aug 2014 05:53
26 Aug 2014 15:16
25 Jul 2014 09:40
23 Jul 2014 14:17
Sector movers: Weak results, outlook from Glaxo sink pharma stocks
A slump in the share price of GlaxoSmithKline dragged the pharmaceuticals and biotechnology sector into the red on Wednesday as the drugmaker disappointed with a drop in quarterly sales and its full-year outlook. The company announced at midday that it has slashed its 2014 outlook as it reported a
Read more18 Jun 2014 13:29
ReNeuron well set after 'transformational' year
Stem cell treatment developer ReNeuron lost an increased £7.1m in a "transformational" year to end-March but still had plenty of cash in the bank as it moves into new cell manufacturing facility and files an investigational new drug (IND) application in the US early next year. The AIM-listed compa
Read more18 Jun 2014 11:47
UK MIDDAY BRIEFING: BOE Policy Makers Still Unanimous
LONDON (Alliance News) - Bank of England policymakers unanimously decided to leave the key interest rates and asset purchase programme unchanged at the monetary policy meeting held on June 4 and 5, the minutes of the meeting showed Wednesday.
All nine members of the Monetary Policy
18 Jun 2014 08:27
ReNeuron Confident For Future Despite Loss As It Advances Therapies
LONDON (Alliance News) - ReNeuron Group PLC Wednesday expressed confidence in its future as it continued to develop its stem-cell therapies towards commercialisation, and it posted a widened loss in the year to end-March. The company posted a pretax loss of GBP7.8 million, widened from GBP7
Read more18 Jun 2014 07:21
UK MORNING BRIEFING: Zoopla Prices IPO As Markets Await Central Banks
LONDON (Alliance News) - UK shares have opened higher Wednesday, following a firm close on Wall Street and ahead of central bank announcements in the UK and US.
There was further IPO activity Wednesday, as property website Zoopla Property Group said it will price it
7 May 2014 14:15
ReNeuron Says Stroke Disability Therapy Study Yielding "Encouraging" Results
LONDON (Alliance News) - Stem cell therapy company ReNeuron Group PLC Wednesday said that its PISCES study of its ReN001 stem cell therapy for stroke disability has continued to yield encouraging results. The company said that there was no cell-related or immunological adverse events report
Read more23 Apr 2014 12:02
ReNeuron seeks to expand board with new CEO
A new chief executive is being sought by AIM-listed stem cell specialist ReNeuron as it enters the next stage of its development. Current Chief Executive Michael Hunt will remain in the role until a replacement is recruited, when he will become Chief Financial Officer. Chairman Bryan Morton said:
Read more23 Apr 2014 11:37
ReNeuron Seeking New Chief Executive, Current To Become Financial Officer
LONDON (Alliance News) - ReNeuron Group PLC said Wednesday that it was appointing a new Chief Executive Officer to replace Michael Hunt, who will be moving into the role of Chief Financial Officer when a successor has been recruited. The company said that, as a result of the progress it has
Read more